RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+50.65%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$5.42B
AUM Growth
+$1.85B
Cap. Flow
+$509M
Cap. Flow %
9.4%
Top 10 Hldgs %
46.89%
Holding
89
New
20
Increased
11
Reduced
36
Closed
9
Avg Time Held
1.2 years
Top 10 Avg Time Held
1.2 years
Top 20 Avg Time Held
1 year

Top Buys

Rank Stock Value
1
ADCT icon
ADC Therapeutics
ADCT
+$210M
2
BNTX icon
BioNTech
BNTX
+$145M
3
IMMU
Immunomedics Inc
IMMU
+$102M
4
PLRX icon
Pliant Therapeutics
PLRX
+$90.5M
5
RPTX icon
Repare Therapeutics
RPTX
+$76.6M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$128M
2
QURE icon
uniQure
QURE
+$90.1M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$75.7M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$56.7M
5
CNC icon
Centene
CNC
+$49M

Sector Composition

Rank Sector Weight
1 Healthcare 98.59%
2 Industrials 1.02%
3 Financials 0.23%
4 Miscellaneous 0.16%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
FATE icon
1
Fate Therapeutics
FATE
$232M
$433M 8%
12,629,737
+1,412,928
+13% +$42.1M
2015 Q2
20 quarters
FOLD icon
2
DELISTED
Amicus Therapeutics
FOLD
$376M 6.94%
24,944,695
-236,805
-0.9% -$2.89M
2013 Q2
28 quarters
DCPH icon
3
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$297M 5.49%
4,978,941
-137,322
-3% -$7.35M
2017 Q3
11 quarters
ADCT icon
4
ADC Therapeutics
ADCT
$185M
$259M 4.78%
+5,525,870
New +$210M
2020 Q2
0 quarters
ARGX icon
5
argenx
ARGX
$51.4B
$233M 4.3%
1,034,868
-47,202
-4% -$8.38M
2017 Q4
10 quarters
IGMS icon
6
DELISTED
IGM Biosciences
IGMS
$230M 4.24%
3,144,000
– –
2019 Q3
3 quarters
BNTX icon
7
BioNTech
BNTX
$22.3B
$205M 3.78%
3,069,164
+2,898,964
+1,703% +$145M
2019 Q4
2 quarters
ALLK icon
8
DELISTED
Allakos
ALLK
$188M 3.47%
2,619,080
-357,848
-12% -$24M
2018 Q3
7 quarters
PRNB
9
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$162M 2.99%
2,712,388
+451,300
+20% +$27.9M
2019 Q2
4 quarters
MNTA
10
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$157M 2.89%
4,705,308
-469,700
-9% -$15M
2019 Q4
2 quarters
EPZM
11
DELISTED
Epizyme, Inc
EPZM
$136M 2.52%
8,485,605
-282,870
-3% -$4.94M
2017 Q3
11 quarters
IMMU
12
DELISTED
Immunomedics Inc
IMMU
$124M 2.28%
+3,489,900
New +$102M
2020 Q2
0 quarters
PLRX icon
13
Pliant Therapeutics
PLRX
$55.3M
$111M 2.04%
+3,410,657
New +$90.5M
2020 Q2
0 quarters
ONEM
14
DELISTED
1Life Healthcare
ONEM
$109M 2.02%
3,010,684
-112,700
-4% -$3.17M
2020 Q1
1 quarter
ATRA icon
15
Atara Biotherapeutics
ATRA
$96.2M
$99.7M 1.84%
273,735
+62,000
+29% +$15.7M
2014 Q4
22 quarters
BEAM icon
16
Beam Therapeutics
BEAM
$2.44B
$94M 1.74%
3,356,958
-2,300
-0.1% -$49.6K
2020 Q1
1 quarter
CI icon
17
Cigna
CI
$76.5B
$91.2M 1.68%
486,100
+185,500
+62% +$35.2M
2019 Q4
2 quarters
APRE icon
18
Aprea Therapeutics
APRE
$7.48M
$88M 1.62%
113,436
– –
2019 Q4
2 quarters
RGNX icon
19
Regenxbio
RGNX
$455M
$82.4M 1.52%
2,236,766
-101,700
-4% -$3.79M
2017 Q1
13 quarters
ZNTL icon
20
Zentalis Pharmaceuticals
ZNTL
$221M
$79.8M 1.47%
+1,661,205
New +$63.7M
2020 Q2
0 quarters
REPL icon
21
Replimune Group
REPL
$1.07B
$77.1M 1.42%
3,104,193
+123,700
+4% +$2.19M
2018 Q3
7 quarters
RPTX icon
22
DELISTED
Repare Therapeutics
RPTX
$74M 1.37%
+2,386,174
New +$76.6M
2020 Q2
0 quarters
GNMK
23
DELISTED
GenMark Diagnostics, Inc
GNMK
$72.1M 1.33%
+4,903,400
New +$49.8M
2020 Q2
0 quarters
NGNE icon
24
Neurogene
NGNE
$443M
$67.1M 1.24%
202,061
– –
2019 Q4
2 quarters
HRC
25
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$64.2M 1.19%
+585,000
New +$61.3M
2020 Q2
0 quarters
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2020 Portfolio in Review

As of Q2 2020, Redmile Group held 89 positions worth $5.42B, up 52% from $3.57B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Redmile Group deployed $509M of net new capital in Q2 2020, opening 20 new positions and adding to 11 existing holdings. Its largest new stake was ADC Therapeutics: 5,525,870 shares worth $259M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Biogen, an estimated $128M trimmed.

  • Redmile Group's largest Q2 2020 buy was ADC Therapeutics: 5,525,870 shares worth $259M.
  • Redmile Group added most to BioNTech in Q2 2020, an estimated $145M increase.
  • Redmile Group's biggest Q2 2020 reduction was Biogen, cutting an estimated $128M.
  • Redmile Group fully exited Seagen Inc. Common Stock in Q2 2020, selling an estimated $75.7M.
  • Redmile Group's ten largest holdings make up 47% of its $5.42B portfolio in Q2 2020.
  • Redmile Group opened 20 new positions and closed 9 in Q2 2020.
  • Redmile Group's portfolio value rose 52% quarter-over-quarter to $5.42B.

Based on Redmile Group's 13F filing for Q2 2020, filed 14 Aug 2020.